Relay Therapeutics to Present at Two Key Healthcare Conferences in March
Event summary
- Relay Therapeutics will participate in fireside chats at TD Cowen's 46th Annual Health Care Conference on March 2, 2026, and Barclays' 28th Annual Global Healthcare Conference on March 11, 2026.
- The company's lead clinical asset, zovegalisib, is in a Phase 3 trial for HR+/HER2- metastatic breast cancer and is also being investigated for PI3Kα-driven vascular anomalies.
- Relay's pipeline includes programs for NRAS-driven solid tumors and Fabry disease.
The big picture
Relay Therapeutics' participation in high-profile investor conferences comes at a critical juncture for the company, as it seeks to highlight its lead asset, zovegalisib, and broader pipeline. The precision medicine sector is increasingly competitive, with investors closely watching the clinical and commercial potential of novel therapies. Relay's ability to articulate its strategic vision and execution plan will be key to maintaining momentum in the market.
What we're watching
- Clinical Progress
- The pace at which zovegalisib advances through its Phase 3 trial and potential approval timelines.
- Pipeline Development
- How Relay Therapeutics' other programs for NRAS-driven solid tumors and Fabry disease progress.
- Investor Sentiment
- Whether the upcoming investor conferences will shift market perception of Relay Therapeutics' valuation.
Related topics